Keywords: merck, crixivan, new, study, data, co, protease

Merck's Crixivan: new study data

Article | 02 October 1995

Print This

- Merck & Co's protease inhibitor Crixivan (indinavir sulfate; MK-639) slowed the rate of CD4 cell destruction by 44% over a 24-week period, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in